HPGC RENMINTONGTAI PHARMACEUTICAL CORPORATION Financials HPGC Renmintongtai Pharmaceutical Corporation
Equities
600829
CNE000000G05
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.45 CNY | +0.78% |
|
+3.86% | -17.52% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,381 | 3,955 | 4,303 | 3,897 | 3,700 | 4,535 |
| Enterprise Value (EV) 1 | 3,099 | 4,109 | 4,497 | 4,421 | 3,787 | 4,240 |
| P/E ratio | 13.1 x | 14.8 x | 29.7 x | 14.1 x | 14 x | 15.5 x |
| Yield | - | - | 1.62% | - | - | 1.84% |
| Capitalization / Revenue | 0.48 x | 0.47 x | 0.54 x | 0.42 x | 0.38 x | 0.44 x |
| EV / Revenue | 0.44 x | 0.49 x | 0.56 x | 0.47 x | 0.39 x | 0.41 x |
| EV / EBITDA | 7.79 x | 10.1 x | 16.7 x | 10.3 x | 9.29 x | 9.85 x |
| EV / FCF | 10 x | -8.81 x | -95.9 x | -28.7 x | 9.25 x | 11.6 x |
| FCF Yield | 9.96% | -11.4% | -1.04% | -3.48% | 10.8% | 8.65% |
| Price to Book | 2.14 x | 2.14 x | 2.16 x | 1.77 x | 1.5 x | 1.65 x |
| Nbr of stocks (in thousands) | 579,889 | 579,889 | 579,889 | 579,889 | 579,889 | 579,889 |
| Reference price 2 | 5.830 | 6.820 | 7.420 | 6.720 | 6.380 | 7.820 |
| Announcement Date | 3/1/19 | 4/10/20 | 3/19/21 | 3/25/22 | 3/27/23 | 3/27/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 7,055 | 8,354 | 8,005 | 9,315 | 9,641 | 10,390 |
| EBITDA 1 | 397.9 | 408.2 | 270 | 427.2 | 407.5 | 430.5 |
| EBIT 1 | 369.3 | 382.3 | 245.5 | 404.9 | 387.9 | 411.7 |
| Operating Margin | 5.23% | 4.58% | 3.07% | 4.35% | 4.02% | 3.96% |
| Earnings before Tax (EBT) 1 | 345.7 | 361.3 | 219.7 | 358.6 | 345.6 | 393.4 |
| Net income 1 | 257.9 | 267.3 | 145.3 | 277.3 | 263.4 | 292.2 |
| Net margin | 3.65% | 3.2% | 1.81% | 2.98% | 2.73% | 2.81% |
| EPS 2 | 0.4447 | 0.4600 | 0.2500 | 0.4782 | 0.4543 | 0.5038 |
| Free Cash Flow 1 | 308.7 | -466.5 | -46.88 | -154 | 409.5 | 366.9 |
| FCF margin | 4.38% | -5.58% | -0.59% | -1.65% | 4.25% | 3.53% |
| FCF Conversion (EBITDA) | 77.59% | - | - | - | 100.48% | 85.21% |
| FCF Conversion (Net income) | 119.72% | - | - | - | 155.42% | 125.57% |
| Dividend per Share | - | - | 0.1200 | - | - | 0.1440 |
| Announcement Date | 3/1/19 | 4/10/20 | 3/19/21 | 3/25/22 | 3/27/23 | 3/27/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 154 | 194 | 524 | 86.9 | - |
| Net Cash position 1 | 282 | - | - | - | - | 295 |
| Leverage (Debt/EBITDA) | - | 0.3784 x | 0.7182 x | 1.226 x | 0.2132 x | - |
| Free Cash Flow 1 | 309 | -467 | -46.9 | -154 | 409 | 367 |
| ROE (net income / shareholders' equity) | 16.2% | 15.6% | 7.55% | 13.2% | 11.3% | 11.2% |
| ROA (Net income/ Total Assets) | 4.99% | 4.8% | 2.66% | 3.97% | 3.51% | 3.55% |
| Assets 1 | 5,169 | 5,571 | 5,463 | 6,982 | 7,501 | 8,224 |
| Book Value Per Share 2 | 2.720 | 3.190 | 3.440 | 3.790 | 4.250 | 4.740 |
| Cash Flow per Share 2 | 0.8700 | 0.6400 | 0.7200 | 1.390 | 2.040 | 2.270 |
| Capex 1 | 5.73 | 8.33 | 14 | 12.2 | 6.42 | 23.5 |
| Capex / Sales | 0.08% | 0.1% | 0.17% | 0.13% | 0.07% | 0.23% |
| Announcement Date | 3/1/19 | 4/10/20 | 3/19/21 | 3/25/22 | 3/27/23 | 3/27/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -17.52% | 516M | |
| +17.35% | 71.39B | |
| +2.39% | 25.1B | |
| -2.98% | 8.59B | |
| +6.69% | 8.19B | |
| -20.96% | 7.91B | |
| +0.49% | 4.54B | |
| +17.12% | 4.31B | |
| -2.61% | 3.86B | |
| +22.08% | 3.64B |
- Stock Market
- Equities
- 600829 Stock
- Financials HPGC Renmintongtai Pharmaceutical Corporation
